Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.54 |
| ▸ | ATM | Q13315 | 10/20 | 0.50 |
| ▸ | PRKDC | P78527 | 8/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | SERPINA2 | P20848 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572084 | 0.93 | ATR (0.54) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL21572086 | 0.90 | ATR (0.54) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL19236408 | 0.90 | ATR (0.67) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL13137803 | 0.85 | ATR (0.45) | ATRATMPRKDC | |
| SCHEMBL17826094 | 0.85 | ATR (0.42) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL18180865 | 0.79 | ATR (0.61) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL18180864 | 0.79 | ATR (0.59) | ATRATMPRKDCJAK2ABL1 | |
| SCHEMBL13137806 | 0.79 | ATR (0.45) | ATRATMPRKDC | |
| SCHEMBL21572085 | 0.78 | ATR (0.62) | ATRATMPRKDC | |
| SCHEMBL18180948 | 0.78 | ATR (0.60) | ATRATMPRKDCJAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-11-19 | — | — | US | disclosed |
| US-9365557-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | ATR, CHEK2, CHEK1 | ATR 1/4885ATM 28/4885PRKDC 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.